【Exhibition Preview】July 25-28, AM Biotech to Showcase Innovative Technologies, Ingredients, and New Products at the Asia Healthcare & Medical Cosmetology Expo 2024

Biotechnology ✕ Beauty and Health "Asia Healthcare & Medical Cosmetology Expo 2024" showcases projects covering

AM Biotech Bio-Pulsed Exosomes entered the top 5 finalists pioneering innovation “Estée Lauder (NIV) BRKTHRU VOICES Prize” at 2024 in-Cosmetics Global

Ascension Medical Biotechnology Co. Ltd.” (AM BIOTECH) is a Taiwan medical biotechnology research company, producer

We are excited to announce our participation at 𝐈𝐧-𝐂𝐨𝐬𝐦𝐞𝐭𝐢𝐜𝐬 𝟐𝟎𝟐𝟒 in Paris!

We are excited to announce our participation at 𝐈𝐧-𝐂𝐨𝐬𝐦𝐞𝐭𝐢𝐜𝐬 𝟐𝟎𝟐𝟒 in Paris, April 16-18. This

According to the EUROPE DIRECT CONTACT CENTRE Consultation Response: ExoGiov Comes from SPF Eggs and Does Not Fall under the Categories Mentioned in ANNEX II/419

All cosmetics related to animal sources and derived ingredients will be labeled ANNEX II/419. However,

AM Biotech’s Unique Bio-pulsed Exosome, Backed by Patents, Shows Bright Prospects in the Global Market

Chairman of AM Biotech, shared the strategic layout of the “bio-pulse induced exosome Technology Platform.”

Chairman of AM Biotech Went to The 49th Annual Meeting of Taiwanese Dermatological Association (TDA) to Give A Special Lecture

Special Lecture at the 2024 Taiwan Dermatology Annual Conference. Discussing the efficiency and mechanism of

Bio-Pulsed Exosome with innovative patented technology from AM Biotech to restore health and beauty

Ascension Medical Biotechnology company(AM Biotech) from Taiwan focusing on the research and development of induced

The Key to Skin Repair: The Fantastic Bio-Pulsed Exosomes

Ascension Medical Biotechnology Co., Ltd. (abbreviation: AM BioTech) is the first in Taiwan and the

The Emergent Role of Exosome Therapy in 2021

Exosomes are extracellular vesicles (EV) derived from endosomes, ranging in size from 30nm to 150nm.

The Therapeutic Potential of Exosomes

In recent years, several universities and research hospitals have conducted small-scale phase I clinical trials